Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGONUE)

Drug Name

AB680 Drug Info

Synonyms

AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH

Indication

Disease Entry	ICD 11	Status	REF
Pancreatic cancer	2C10	Phase 1	[1]

Cross-matching ID

PubChem CID: 130205852
CAS Number: CAS 2105904-82-1
TTD Drug ID: DMGONUE

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Ecto-5'-nucleotidase (CD73)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TJ004309	DMFB54Y	Ovarian cancer	2C73	Phase 2	[3]
GS-1423	DMS25DL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
Oleclumab	DMLVNWO	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
TJ4309	DMM3U2Q	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
CPI-006	DMJSFTX	Advanced cancer	2A00-2F9Z	Phase 1	[7]
LY3475070	DMZLIWX	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
NZV930	DMWN2FP	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
PMID28870136-Compound-57	DME3HLC	N. A.	N. A.	Patented	[10]
PMID28870136-Compound-46	DM4FD7C	N. A.	N. A.	Patented	[10]
PMID28870136-Compound-53	DMLEWY6	N. A.	N. A.	Patented	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ecto-5'-nucleotidase (CD73)	TTK0O6Y	5NTD_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04104672) A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies. U.S. National Institutes of Health.
2	Discovery of AB680: A Potent and Selective Inhibitor of CD73. J Med Chem. 2020 Oct 22;63(20):11448-11468.
3	ClinicalTrials.gov (NCT05001347) A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ?) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors. U.S.National Institutes of Health.
4	Clinical pipeline report, company report or official report of Agenus.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	ClinicalTrials.gov (NCT04322006) A Phase I/II Study of TJ004309 for Advanced Solid Tumor. U.S. National Institutes of Health.
7	Clinical pipeline report, company report or official report of Corvus Pharmaceuticals.
8	CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. Front Immunol. 2020 Apr 15;11:508.
9	Clinical pipeline report, company report or official report of Surface oncology.
10	Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.